Treatment for Hepatitis C

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Mississippi Medical Center, Jackson, MS
Hepatitis C+1 More
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether targeted screening for hepatitis C is more effective than nontargeted screening.

See full description

Eligible Conditions

  • Hepatitis C

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome, 2 secondary outcomes, and 6 other outcomes in patients with Hepatitis C. Measurement will happen over the course of 1 day from ED visit.

Day 1
HCV test acceptance
HCV test completion
Newly diagnosed active HCV
Month 12
Completion of an evaluation by an HCV treatment expert
Completion of treatment with Direct-Acting Antivirals (DAAs)
Fibrosis staging
HCV genotype among those identified with active HCV
Initiation of treatment with Direct-Acting Antivirals (DAAs)
Sustained virologic response at 12 weeks after treatment completion (SVR12)

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

This trial requires 165000 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months following hcv diagnosis
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 12 months following hcv diagnosis for reporting.

Who is running the study

Principal Investigator
J. H.
Prof. Jason Haukoos, Professor & Director of Research, Department of Emergency Medicine, Denver Health
Denver Health and Hospital Authority

Closest Location

University of Mississippi Medical Center - Jackson, MS

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Present to EDs during study enrollment period
Clinically stable per screening nurse or physician assessment
Able to provide consent for medical care

Patient Q&A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Hepatitis C by sharing your contact details with the study coordinator.